致癌曝光仪Quickfire挑战
Up to $250,000+指导
Winner
PExAis developing a non-invasive method for sampling of biological material from Respiratory Tract Lining Fluid (RTLF) from human’s most distal airways, advancing new possibilities for the development of potentially more accurate diagnostics and effective drugs.
The Challenge
在21世纪，预计在20世纪，烟草的使用索赔了超过1亿人的生活。根据纽约时报，数百万美元在教育公众对习惯的毁灭性影响。然而，数百万的人，包括3200名青年和青少年在美国，可以选择每天开始吸烟。
Cigarettes release more than 7,000 chemicals when burned, of which at least 69 are known to cause canceraccording to Lung.org。这种致命的化学鸡尾酒每年有贡献超过600万人死亡，每隔五秒钟转化为一只吸烟死亡。根据疾病控制和预防的中心，是肺癌的危险因素，与美国肺癌约80％左右。
Preventing tobacco use among the youth is critical to ending the world-wide tobacco epidemic. Yet, billions of smokers choose not to heed statistical warnings. They maintain a habit, which will reduce their life expectancy by at least 10 years on average. Would that change, however, if we could measure the effect of carcinogens in real time? Is a smoker more likely to quit when they can quantify the damage they are causing to their body? Much like stepping on a scale can help improve weight loss, could a carcinogenic exposure meter be a key smoking cessation tool?
To that end, Janssen Research & Development, LLC and Johnson & Johnson Innovation, JLABS are launching theCarcinogenic Exposure Meter QuickFire Challenge, aimed to help foster innovation that can measure the impact of cigarettes with the goal of reducing tobacco use by motivating young smokers to quit smoking. Innovators from across the world are invited to develop “carcinogenic exposure meters” to better quantify the damage known to play a role in carcinogenesis resulting from exposure to tobacco.
[1]Jha P. et al. Chapter 10 of: Cancer: Disease Control Priorities, Third Edition (Volume 3) (2015).
[2]疾病控制和预防中心;
[3]谁报告全球烟草流行病，2017年。监测烟草使用和预防政策。
[4]USA Today
Awards
- 指导from experts at Johnson & Johnson Innovation
Criteria
We are looking for proposals that develop approaches and/or devices to measure damage known to play a role in carcinogenesis resulting from exposure to tobacco smoke, using minimally invasive sampling methods, preferably at points of care.
The desired biological effect to be measured would reflect a combination of the degree of exposure and the degree of susceptibility. Damage markers should be recognized as playing a role in carcinogenesis. Ideally, smoking cessation should result in return to normal non-smoking levels of the damage marker.
Proposals containing the following criteria are preferred but are not required.请记住，不想太大或过早考虑。在评估期间也会考虑清楚地描述实现这些目标的概念或道路的应用。
The Carcinogenic Exposure Meter should:
- 尽可能微创，以便在各种护理点采样。
- 区分平均环境暴露和烟草的影响。
- Include clinical data from human studies. If unavailable, applicants are encouraged to provide a detail path forward to proof-of-concept.
Areas of Interest
- 消费产品
- In Vitro Diagnostic (IVD) Medical devices
- Health technologies
- Cross-sector initiatives – an integration of one or more the aforementioned areas of focus
Timeline
申请流程
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential to impact healthcare outcomes in a strategic area of interest
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Clarity of plan: Milestones & defined go/no go decisions
为什么这一挑战对我们很重要
我们相信一个好主意可以来自任何地方，我们的目标是寻找为来自世界各地的患者提供解决方案的新技术。在一起，我们可以激发一个将改变健康轨迹的下一个好主意。
常问问题s
What if I’m having trouble accessing the portal/website?
Make sure your browser is up to date and accepting cookies. You can contact customer service at https://jnjawards.fluidreview.com/helpdesk/contact/ if you are having technical difficulties as well.
Can I submit supporting documents (for example a video) as part of my application?
您将有机会，并鼓励以申请的一部分上传幻灯片，研究论文和视频等支持材料。您可以提交视频以及您的类型的响应。最大长度为2分钟。
Is it ok if some of the information I submit is confidential?
不提交机密信息。只有非onfidential information should be submitted and anything you submit will be treated as non-confidential.
IP（知识产权）会发生什么？
As this is a no strings attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.
Is a patent required to apply?
No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
什么样的科学/技术适合挑战？
我们鼓励所有人申请。了解更多关于我们愿意探索的地区的更多信息：https://www.jnjinnovation.com/partnering
Who is eligible to apply?
Each Challenge has its own terms & conditions that can be found prior to filling out the application.
What are the specific criteria for application?
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- 明确的计划和里程碑
Who can I contact if I have questions about the Challenge or the application process?
Please contact[电子邮件受保护]with any questions.
Where do I apply? And do I have to complete the application in one sitting?
You can setup an account at http://jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.
About the Janssen Pharmaceutical, Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.We are Janssen. We collaborate with the world for the health of everyone in it. Learn more atwww.janssen.com。Follow us at@JanssenGlobal。
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
jlabs.currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto, and in NYC in collaboration with the New York Genome Center. Recently, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe and JLABS @ Shanghai will open in 2019. For more information about JLABS, please visitwww.www.2574design.com。
About Johnson & Johnson Innovation
ld乐动强生公司创新有限责任公司专注于加速rating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.